Independent Confirmation That Menstrual Derived Stem Cells Have Utility in Fighting Disease

Wed Apr 23, 2008 9:40am EDT

* Reuters is not responsible for the content in this press release.

  SAN DIEGO, CA and SCOTTSDALE, AZ, Apr 23 (MARKET WIRE)
-- 
 Medistem Laboratories, Inc. (OTCBB: MDSM), a biotechnology company dedicated to
commercializationof its novel, universal donor, stem cell population, the
Endometrial Regenerative
Cell (ERC), applauds a recent publication from an independent Japanese group
describing a similar cell type to Medistem's ERC from the same source:
menstrual blood.

    The recent publication "Hida et al. Novel Cardiac Precursor-Like Cells
fromHuman Menstrual Blood-Derived Mesenchymal Cells. Stem Cells. 2008 Apr 17
[Epub ahead of print]" describes a stem cell population capable of not
onlybecoming heart tissue in vitro, but also having ability to repair injured
hearts
in animal models of heart attacks.

    "These recent data provide independent unbiased verification of the presence
of functional stem cells in the menstrual blood," said Thomas Ichim, CEO of
Medistem.  He continued, "Our previous publication and patent applications
describe a cell population with phenotypic and functional similarities to the
cells
of Hida et al.  We are pleased to have aspects of our work successfully
reproduced and advanced by scientists at the prestigious Keio University
School of Medicine, Tokyo."

    In November 2007, an international group of scientists lead by Medistem
announced
the discovery of the "Endometrial Regenerative Cell," a menstrual blood derived
stem cell that could differentiate into 9 major tissues, produce high levels of
therapeutic factors, and was capable of massive in-vitro expansion.  The study,
which is freely available at
http://www.translational-medicine.com/content/5/1/57 was awarded BioMed
Central's Best Publication in Medicine of 2007.

    "Medistem has more than 15 patent families dealing with adult stem cell
therapeutics.  The recent publication provides additional support for the
menstrual blood derived stem cell populations as a viable alternative to
embryonic stem cells," said Neil Riordan, Chairman of Medistem.

    About Medistem Laboratories

    Medistem Laboratories is a biotechnology company founded to develop and
commercialize technologies related to adult stem cell extraction, manipulation,
and
use for treating inflammatory and degenerative diseases. The company's lead
product, the endometrial regenerative cell (ERC), is a "universal donor"
stem cell derived from the menstrual blood that possesses the ability to
differentiate into nine tissue types, produce large quantities of growth
factors, and a large proliferative capacity. Due to Medistem's relationships
and collaborative efforts with respected institutions, Medistem believes it is
well
positioned to be a leading developer of adult stem cell products.

    Cautionary Statement

    This document does not constitute an offer to sell or a solicitation of an
offer to buy any of our securities. This document contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act
of 1934, as amended. These forward-looking statements may include projections
of matters that affect revenue, the ability to develop or license certain
technologies and receive associated licensing fees; operating expenses or net
earnings; projections of capital expenditures; projections of growth; hiring
plans;
plans for future operations; financing needs or plans; plans relating to the
company's products and services; and assumptions relating to the foregoing.

    Forward-looking statements are inherently subject to risks and
uncertainties,
some of which cannot be predicted or quantified. Future events and actual
results could differ materially from those set forth in, contemplated by, or
underlying the forward-looking information.

    Some of the important factors that could cause the company's actual
resultsto differ materially from those projected in forward-looking statements
made by the
company include, but are not limited to, the following: the company's ability
to anticipate future license fees, technology development limitations, intense
competition, risk of business interruption, management of rapid growth, need for
additional financing, regulatory approvals and requirements, dependence on
key personnel and research, management and other administrative costs.

    These factors are discussed in greater detail in the company's quarterly and
annual
periodic reports, all as filed with the Securities and Exchange Commission.

    

Contact:
Medistem Laboratories
Chris McGuinn
602-318-3535
http://www.medisteminc.com

Copyright 2008, Market Wire, All rights reserved.

-0-